Metformin is sold under several trade names, including Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor, Metfogamma and Glifor. The USDA cites it as a weed.

While endless pharmacovigilance has monitored the safety profile of metformin, its natural ancestor, G. officinalis (known as Professor Weed in the USA) is a Class A Federal Noxious Weed in 35 states of America, and appears on the database of poisonous plants. (Wiley)


The discovery of metformin dates back to 17th century. Galega officinalis L., also known as the French lilac, was used as a herbal remedy to relieve the intense urination caused by the diabetes mellitus in medieval times [1]. The guanides are rich in French lilac and essential compounds in lowering blood glucose, which led to development of three biguanides, metformin, phenformn, and buformin. Among them metformin was found to be the most useful drug because of its low toxicity. It was first synthesized in 1922, but approved for treatment of diabetes in Europe until 1950s and by FDA in USA in 1994. It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.[15]

Galega officinalis Linn was a herbal medicine in medieval Europe. G. officinalis (Leguminosae) is a perennial herb with white, blue or purple flowers that grows over three feet high and is found in most temperate regions, including Britain. Its common names include goat’s rue, French lilac, Spanish sanfoin and false indigo  Aerial parts of the plant were used medicinally in medieval Europe to treat plague, worms, snake bites, miasma, dysuria and St Vitus dance, and the plant was fed to livestock to increase milk yield.


Why Supplement?

  • Metformin’s main effect is to decrease liver glucose production.[79] It also has an insulin-sensitizing effect with multiple actions on tissues including the liver, skeletal muscle, endothelium, adipose tissue, and the ovary.[38][95]
  • Metformin decreases high blood sugar, primarily by suppressing liver glucose production (hepatic gluconeogenesis).[79]
  • A 2017 review and meta-analysis found that people with diabetes who were taking metformin had 7% lower all-cause mortality. They also had reduced cancer (breast, gastrointestinal, liver, pancreatic) than those on other therapies.
  • Numerous epidemiologic studies have shown an association of metformin use with a decreased risk of cancer, as well as decreased cancer mortality. (There is also evidence from studies performed both in-vitro and in-vivo of metformin’s role in attenuating tumorigenesis. The mechanisms proposed relate to its effects on reducing insulin levels, improving insulin action, decreasing IGF-1 signaling (central to mammalian longevity), and reducing the senescent process (senolytics) as well as activation of AMP-kinase.
  • A large population-based study evaluated the effect of metformin on five-year survival. Records of 78,000 diabetic patients treated with metformin were compared with records of 78,000 non-diabetic subjects and matched for relevant characteristics, such as age, smoking, cancer history, etc. Similar comparison was performed between 12,000 diabetic patients taking sulphonylurea (SU) drugs and 12,000 matched non-diabetic individuals. Not unexpectedly, SU-treated diabetic patients had ~40 percent greater mortality than their non-diabetic control group. However, mortality in metformin-treated diabetic patients was similar to the matched non-diabetic controls. In fact, among patients in their 70s, mortality was reduced by ~15 percent in metformin-treated diabetic patients compared with non-diabetic controls. These observations suggested that the protective action of metformin may extend beyond effects on specific age-related diseases. It was used to provide compelling evidence to support the design and conduct of studies to directly test whether human aging, and its diseases, could be effectively delayed.
  • 40% of humans are non-responders to metformin, so only get the side-effects.

Leading Anti-Aging Scientists taking Metformin include:

  • Ray Kurzweil
  • David Sinclair
  • Nobel laureate James Watson
  • Ned David, cofounder of Silicon Valley startup Unity Biotechnology
  • Robert Hariri, co-founder and president of Human Longevity Cellular Therapeutics


Clinical Trials?

Side Effects and Adverse Events?

Data Sources:

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Related posts
Keep Health Factors

The Wealth Health Connection

Future Home PageLeading-Edge Research


Future Home PageLeading-Edge Research

Cellular Reprogramming


Dark Chocolate Health Benefits

Leave a Reply

Your email address will not be published. Required fields are marked *